A number of tools based on high-performance affinity separations have been developed for studying drug-protein interactions. An example of one recent approach is ultrafast affinity extraction. This method has been employed to examine the free (or non-bound) fractions of drugs and other solutes in simple or complex samples that contain soluble binding agents. These free fractions have also been used to determine the binding constants and rate constants for the interactions of drugs with these soluble agents. This report describes the general principles of ultrafast affinity extraction and the experimental conditions under which it can be used to characterize such interactions. This method will be illustrated by utilizing data that have been obtained when using this approach to measure the binding and dissociation of various drugs with the serum transport proteins human serum albumin and alpha 1 -acid glycoprotein. A number of practical factors will be discussed that should be considered in the design and optimization of this approach for use with single-column or multi-column systems. Techniques will also be described for analyzing the resulting data for the determination of free fractions, rate constants and binding constants. In addition, the extension of this method to complex samples, such as clinical specimens, will be considered.
Introduction
The extent of binding by many drugs to serum proteins can play a significant role in determining the eventual activity and fate of these drugs in the circulation [1, 2] . This makes the measurement of a drug's ability to bind to these proteins an important item to consider during the discovery, development and use of a new pharmaceutical [2] . The binding of a drug with agents in blood is often reversible and results in both bound and free fractions for the drug. Because the bound form of a drug cannot usually cross a cell membrane or bind to a receptor, it is the free fraction that often determines the overall activity of the drug [1] [2] [3] [4] . Two serum proteins that bind to a broad range of drugs are human serum albumin (HSA) and alpha 1 -acid glycoprotein (AGP, or orosomucoid) [2] . More complex agents such as lipoproteins can also be involved in binding to drugs in the circulation [5] [6] [7] [8] [9] [10] [11] .
A number of techniques have been utilized to study and measure the binding of drugs with serum proteins and other biological agents [2, 7, . These methods have included separation-based approaches such as equilibrium dialysis, ultrafiltration, liquid chromatography and capillary electrophoresis. A number of spectroscopic methods have also been employed for this work, such as absorbance, fluorescence, circular dichroism, nuclear magnetic resonance, and surface plasmon resonance spectroscopy. Differential scanning calorimetry and isothermal titration calorimetry have been used as well for this purpose [2, 7, .
Another method that has been explored for studying drug-protein binding is high performance affinity chromatography (HPAC) [1, 3, [34] [35] [36] [37] [38] [39] [40] . In HPAC, a biological binding agent is used as a stationary phase for the isolation or analysis of components in a sample [1] . The retention of injected or applied solutes in HPAC is based on the specific and reversible interactions that occur in biological systems (e.g., drug-protein binding). This type of binding is combined in HPAC with supports such as silica particles or monolithic materials that have good mass transfer properties and are capable of withstanding the pressures and flow rates that are present in systems for high performance liquid chromatography [41] .
HPAC has been used in a variety of formats to determine binding constants for drugprotein interactions, to study drug-solute competition for proteins, to characterize the binding sites for these processes, and to describe the rates of these interactions [1, 42] . Some advantages of using HPAC for this type of work are its speed, precision, ability to be automated, and need for only a small amount of a protein or binding agent. Other attractive features of HPAC are its compatibility with many types of detectors, its good correlation with solution-based methods, and its ability to often reuse the same immobilized binding agent for many samples [1, 3, 12, 42] .
Ultrafast affinity extraction is an HPAC technique that has been recently developed for studying drug-protein binding [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . Figure 1 illustrates the basis of this technique. This method uses an affinity microcolumn to extract the free fraction of a drug from a sample on a time scale that minimizes or allows controlled dissociation of the drug from its soluble binding agents. This approach has been used to measure the free fractions of drugs and other solutes in solute/protein mixtures and in biological samples [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . The same method has also been used to determine equilibrium constants and rate constants for drug-protein interactions [49, 54] .
This report will describe the general principles of ultrafast affinity extraction and various factors to consider when using this method to characterize drug-or solute-protein interactions.
Practical aspects that will be considered will include the types of formats that can be used in this method; factors to optimize when using this method for free fraction measurements; and techniques for analyzing the resulting data to obtain equilibrium constants or rate constants.
These items will be illustrated by using data that have been previously acquired by this method for various drugs that are known to bind to HSA or AGP in serum or blood [44-46,52,53].
Materials
The chemicals and biochemicals that are used in ultrafast affinity extraction should have known purities and be obtained from sources that have good batch-to-batch reproducibilities for these reagents. All buffers and aqueous solutions that are used in this method should be prepared using deionized water, as obtained from water purification devices such as a Milli-Q Advantage A10 system (Millipore, Billerica, MA, USA) or a NANOpure system (Barnstead, Dubuque, IA, USA). The aqueous buffers and solutions employed in ultrafast affinity extraction should ideally be filtered prior to injection or application to an HPLC system, such as by using 0.22 µm GNWP nylon filters from Fisher Scientific (Pittsburgh, PA,USA) or comparable filtration devices.
Solution and mobile phase preparation
The mobile phase used for ultrafast affinity extraction should mimic the pH and solution composition of the biological system that is being examined [1] . For the study of drug interactions with serum proteins, one common mobile phase that is used is 0.067 M potassium phosphate buffer, pH 7.4 [42] . This buffer can be prepared by dissolving 7.546 g of monobasic potassium phosphate and 37.724 g of dibasic potassium phosphate in 4.00 L water. The pH of this solution can then be adjusted to 7.40 by the slow addition of low concentrations of either hydrochloric acid or sodium hydroxide. After this buffer has been prepared and filtered, it should be stored at 4ºC when not in use. Other buffers or solutions can also be used as the mobile phase in ultrafast affinity extraction, depending on the nature of the system and types of interactions that are to be characterized. that have a known volume can be spiked directly with a small volume of a solution that contains a known concentration of the drug to be studied [52, 53] .
A sample/protein mixture that is used in ultrafast affinity extraction should be incubated at the desired temperature for interaction studies (e.g., 37ºC for work under physiological conditions) at least a half hour before it is used in any binding experiments. The individual drug and protein solutions or remaining drug/mixture should be stored, when not in use, under appropriate conditions to provide good stability for these reagents. For serum proteins, this often involves storage of these solutions at 37ºC. However, the length of time over which such solutions can be stored should be determined for each new drug or protein to ensure good stability for these reagents is present over the course of the binding studies.
Preparation of affinity microcolumns
Immobilized HSA or AGP was used as the stationary phase for the affinity microcolumns in the examples provided in this report because of the ability of these serum proteins to undergo fast and reversible binding to a wide range of drugs, as well as their ability to later elute these drugs under isocratic conditions at a physiological pH [1, 48, 50, 55] . The affinity microcolumns and columns that were used in these prior reports had a typical inner diameter of 2.1 mm and lengths of 0.1-5.0 cm. However, other column dimensions can also be employed for ultrafast affinity extraction as long as the total column residence times are suitable for isolation of a free drug fraction. It was found for many drugs that the desired residence times are usually in the range of approximately 0.1-0.9 s when using HSA or AGP as the soluble binding agent [45, 47, 49, 53, 54] .
A variety of supports can be used for HSA or AGP immobilization. The specific examples that were utilized in this report used Nucleosil Si-300-7 porous silica (7 μm particle size, 300 Å pore size) from Macherey-Nagel (Duren, Germany). However, other types of porous silica or even monolithic supports can also be modified for use in this type of work [56] [57] [58] .
Many methods can be used to immobilize HSA onto porous silica or other types of HPLC supports [47, [56] [57] [58] [59] [60] [61] [62] . One common example of such a technique is the Schiff base method, which is illustrated in Figure 2 (a). In this method, a support such as silica is first converted into or obtained in a diol-bonded form [58, 59, 60] . This form enables the support to have low nonspecific binding for many drugs and biological agents and makes this support easy to further modify for the immobilization of proteins or other binding agents [59, 60, 63 ]. The diol groups are then oxidized to aldehyde groups, which can be combined with primary amines on a protein such as HSA to form a Schiff base. The Schiff base is then converted to a secondary amine upon its formation by using sodium cyanoborohydride as a reducing agent. After immobilization has taken place, sodium borohydride is often added to reduce any remaining aldehydes to form alcohol groups [56, 59, 60] .
The following conditions can be used to immobilize HSA to Nucleosil Si-300-7 silica by the Schiff base method. To make 0.10 g of HSA silica, 0.10 g of diol silica is first oxidized to form aldehyde groups by placing this support into 2 mL of 90% acetic acid that contains 0. Several methods have also been applied for immobilizing AGP onto HPLC-grade porous silica [64] [65] [66] . The AGP support that was used in this particular study was prepared using hydrazide-activated silica and mildly-oxidized AGP; this procedure has been shown to produce immobilized AGP with drug binding properties that mimic those for soluble AGP [65, 66] . This hydrazide method is illustrated in Figure 2 (b). In this immobilization scheme, silica is first converted into or obtained in a diol-bonded form and oxidized with periodate to give an aldehyde-activated form [65] . The aldehyde-activated silica is then reacted with an excess of oxalic dihydrazide to give hydrazide-activated support [65] , with remaining aldehyde groups on the support later being reduced by adding sodium borohydride. The hydrazide-activated support is then combined with AGP that has undergone mild oxidation to produce aldehyde groups in its carbohydrate chains, which can form a stable hydrazone bond with the support.
The following conditions can be used to immobilize AGP to Nucleosil Si-300-7 silica by the hydrazide method [65] . To make 0.10 g of AGP silica, 0.10 g of diol silica is first oxidized These conditions result in approximately five aldehyde groups being generated per AGP [66] .
The oxidized AGP can be purified by washing it with 0.10 M phosphate buffer, pH 7.0, in centrifugal filtration devices [64] , with the final volume of the AGP solution then being adjusted to 2.0 mL with the same buffer. This solution of oxidized and purified AGP is mixed with 0.10 g of hydrazide-activated silica, placed on an inversion shaker, and allowed to react for one week at until further use [53, 54] . A control support can be prepared in a similar manner but with no AGP being added to the hydrazide-activated silica during the immobilization step.
In the examples that are cited in this report, microcolumns and columns with various sizes (i.e., lengths of 1-50 mm and 2.1 mm i.d.) were used with the immobilized HSA and AGP supports and control supports. For columns that had lengths of 5 mm or longer, the supports were downward slurry packed into stainless steel columns. The packing pressure was usually 4,000 psi (or 28 MPa) for this type of column. For microcolumns that had lengths below 5 mm, the supports were packed in a similar manner but instead used a frit-in-column design [67] . The typical packing pressure for these shorter columns was 3,000 psi (20 MPa). Either set of packing conditions used a neutral buffer such as 0.067 M phosphate buffer, pH 7.4, as the packing solution, with the columns being stored at 4 °C in the same buffer when not in use.
Apparatus
Most standard HPLC systems can be adapted for use in ultrafast affinity extraction. For the examples given in this report, a single-column chromatographic system for ultrafast affinity extraction usually consisted of such components as a PU-2080 plus pump from Jasco (Easton, MD, USA), a six-port LabPro valve from Rheodyne (Cotati, CA, USA), a Jasco UV-2075 UV absorbance detector, a Jasco AS-2057 plus autosampler, and a Jasco CO-2067 plus column oven.
However, other types of pumps, detectors, autoinjectors and equipment for column temperature control can also be employed for this type of system. The general design for this single-column system is shown in Figure 3 (a). During the binding experiments that were carried out for the examples cited in this report, the temperature of the column oven was often maintained at 37 ºC, although other temperature can also be utilized. The size used for the microcolumn in this system will depend on the affinity of the injected drug/solute for the immobilized binding agent and the flow rates that are to be used for isolation of the free drug/solute fraction [47, [49] [50] [51] [52] .
However, microcolumn sizes in the range of 1-10 mm long and 2.1 mm I.D. have been used in prior work with this approach, with this size tending to increase as the affinity of the injected drug or solute decreases for the immobilized binding agent [48] [49] [50] [51] [52] [53] .
As is shown in going from Figure 3 (a) to 3(b), the basic set up of a two-column system for ultrafast affinity extraction and the equipment used in this system are similar to those for the single-column system. The main additions are a second column, which is usually larger than the first, and a six-port valve, which is used to place the second affinity column in line with the first column. After elution of the non-retained peak from the first column, the position of the six-port valve is switched to carry a portion of the retained peak from the first column and onto the second affinity column. The components eluting from the second column are then monitored by a device such as an absorbance detector. This two-column approach can be used to provide a higher level of resolution between the retained and non-retained drug fractions than can be obtained when using only a single-column system [53] . Typical sizes for the second column in this system have been 5-25 mm long and 2.1 mm I.D., with the column size that is needed again tending to increase as the affinity of the drug/solute decreases for the immobilized binding agent [48, 50, 52, 53] .
Methods

Optimization of ultrafast affinity extraction
The general scheme for the use of a single-column affinity system to measure free drug fractions is shown in Figure 4 (a) [54] . First, the drug and protein mixture is allowed to incubate at the desired temperature prior to injection of this mixture onto an affinity microcolumn that contains an immobilized binding agent for the drug (e.g., immobilized HSA or AGP). At low-tomoderate flow rates, some of the protein-bound drug in the sample will dissociate as the sample passes through the microcolumn, as represented by the top portion of Figure 4 (a). This dissociated drug increases the measured free drug fraction and provides data that can be used to estimate the dissociation rate constant for the soluble drug-protein complex [54] . As the sample passes through the microcolumn at a sufficiently high flow rate, only the original free fraction of the drug is retained by the microcolumn as the soluble, bound form of the drug and excess soluble protein are eluted as a non-retained peak. As is shown in the bottom portion of Figure   4 (a), the free drug fraction that is measured under these conditions can be used to estimate the actual or apparent equilibrium constant for the drug-protein interaction in solution.
Figure 4(a) shows how the residence time for a sample inside an affinity microcolumn can play an important role when using ultrafast affinity extraction to measure free drug fractions [47, 49, [51] [52] [53] [54] . This factor can be modulated by altering either the column size or flow rate
[47, [49] [50] [51] [52] . The effect of changing the flow rate during ultrafast affinity extraction is shown in Figure 5 . In this illustration, the apparent free fraction for a drug decreases as the flow rate is increased from a low-to-moderate level and reaches a constant value at higher flow rate [54] . At the low-to-moderate flow rates (i.e., less than 0.85 mL/min, in this example), some drug that was bound to proteins in the sample is able to dissociate from these proteins, resulting in an increase in the apparent free drug fraction. However, this apparent free drug fraction approaches the true value when the flow rate becomes high enough to keep this dissociation at a negligible level.
The flow rate that is needed to obtain this condition will vary from one drug and protein system to the next, but generally occurs when the sample residence time is on the order of a few hundred milliseconds [47, 49, 51, 53] .
Figure 4(b) shows the general scheme for using ultrafast affinity extraction with a twocolumn system to measure free drug fractions [53] . In this case, an affinity microcolumn and longer affinity column can be connected in series during part of the separation. The drug and protein mixture is first injected onto only the affinity microcolumn, which will extract and retain the free drug fraction from the sample while the bound form of the drug and excess soluble protein elute as non-retained components [50, 52, 53] . For samples that are complex or that contain a large amount of protein, baseline resolution may not always be obtained between the retained and non-retained peaks of the first column. In this situation, a second and longer affinity column can be placed online with the affinity microcolumn after most of the nonretained components have eluted. A part of the free drug fraction that is retained by the first column is then delivered to the second column to enable further separation of the free drug fraction from other sample components [50, 52, 53] .
One important factor to consider during this transfer process is the time that is used to switch the second column online with the first [50, 52, 53] . The effect of varying this time on the measured free drug fraction is illustrated in Figure 6 [53] . When the switching time is short, the result is in an increase in the apparent free drug fraction due to contamination from non-retained components in the sample, as shown in Figure 6 (b). When the switching time is made longer, this contamination is minimized and a consistent free drug fraction is observed. However, using switching times that are too long will also create a loss in precision for the measured free drug fraction as less of the retained peak enters the second column, as demonstrated in both Figures 6(a) and 6(b). As a result, use of an intermediate switching time is generally recommended to provide both good accuracy and reasonable precision for the measured free drug fraction [53] .
Measurement of free drug fractions
The first way ultrafast affinity extraction can be used is to measure the free fraction of a drug in a drug/protein mixture or more a complex sample that contains the drug and binding agents [47] . Figure 7 shows some typical chromatograms from such a study, as obtained with an HSA microcolumn and by using samples that contained the drug tolbutamide or a mixture of tolbutamide and soluble HSA [50] . Once this type of separation has been optimized (i.e., as described in the previous section for work at column residence times that minimize drug-protein dissociation in the sample), the free drug fraction in the sample can be determined by dividing the retained peak area observed for the drug by the total peak area that is measured for a standard that contains the same total concentration of the drug but no protein [50, 52, 53] . 
Determination of rate constants
Another way ultrafast affinity extraction can be employed is to determine the dissociation rate constant (k d ) for a drug-protein complex. This can be accomplished by measuring the free drug fraction at low-to-medium flow rates when a drug-protein mixture is injected onto the affinity microcolumn [49] . The apparent free fractions are then measured, as described in the previous section, and used to prepare a plot according to Eqs. (1) or (2) [49].
(1)
In these two equivalent equations, F 0 is the true original free fraction of drug D in the sample (e.g., as determined at high flow rates), and F t is the apparent free fraction that is measured at low-to-moderate flow rates (i.e., conditions where the drug-protein complex DP is allowed to dissociate for time t in the microcolumn). According to Eqs. (1) and (2) Figure 8 shows some plots that are acquired when using Eqs.
(1) and (2) for kinetic studies, as based on data for the drug verapamil and soluble AGP [54] . Table 1 
Determination of binding constants
Use of a small column residence time can result in free drug fractions that can be employed to estimate the equilibrium constant for a drug-protein interaction (e.g., as related to the original free drug fraction in the initial sample). For instance, a free fraction that is determined under these conditions can be used with Eq. (3) to provide the association equilibrium constant (K a ) for a drug-protein system that has a single-site, saturable interaction Another method that can be used to estimate the equilibrium constants for drugs with soluble proteins is based on the estimate of F 0 that is obtained in kinetic studies when using Eq.
(2) [49] . In this approach, the value of F 0 can be acquired from the intercept of a plot of ln[1/(1 -F t )] versus t, which can then be used along with Eq. (3) to find K a or nK a '. Table 2 lists some association equilibrium constants and global affinities that have been obtained in prior work when using either of these methods for various drugs and soluble forms of HSA or AGP [49, 54] .
A more complex model, as described by Eqs. (4-6), can be used with ultrafast affinity extraction and free fraction measurements to examine the interaction for a drug with two separate binding agents. This type of model has been used to measure the association equilibrium constants or global affinities for a number of drugs in serum which can bind to both AGP and HSA [53] . (4) where,
In these equations K a,A is the apparent or global affinity constant for a drug/analyte with AGP; Ultrafast affinity extraction has been used in equilibrium studies for systems that have varied from weak-to-strong binding [71] . For instance, this method has been used with affinity columns containing antibodies to measure the free fraction of warfarin in samples containing a mixture of this drug and HSA [43] . Ultrafast affinity extraction has also been utilized in combination with flow-based displacement immunoassays to measure the free fractions of thyroxine and phenytoin in clinical samples [44] [45] [46] . In addition, this method has been used to measure the free fractions and equilibrium constants for various drugs with HSA/glycated HSA [47, 49, 50, 52] or AGP [53, 54] and to study the interactions of testosterone with both HSA and sex-hormone binding globulin [51] .
Conclusion
This report has described the method of ultrafast affinity extraction and has shown how this approach can be employed as a tool for studying drug-or solute-protein interactions. The general principles of this method were discussed, along with various experimental factors to consider in the design and optimization of this technique and methods for analyzing the resulting data for equilibrium or kinetic studies. Several applications for this approach were also described. These applications included measurement of the free fractions for drugs and other solutes in simple solutions or biological samples [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] , and the use of this method to characterize the equilibrium constants or rate constants for drug/solute-protein interactions [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . These applications and experimental considerations were illustrated by using data that have been obtained through this method for various drugs and solutes that are known to bind to HSA and AGP and with binding strengths that have ranged from 10 3 to 10 9 M -1 [44-46,52,53].
Several advantages for ultrafast affinity extraction have been noted in these applications.
For instance, this is a label-free method that can be used with a variety of detection techniques [12] . Unlike other common approaches for biointeraction analysis (e.g., traditional HPAC and surface plasmon resonance), this method allows for solute-protein binding to be examined directly in solution, rather than between a solute and immobilized binding agent [12, 49, 51] .
Other appealing features of this method include its ability to work with either low or high affinity systems, its need for only a small amount of sample, and its ability to provide results in few minutes after sample injection [12, 52] . One current limitation of this method is that some preliminary studies must be conducted to determine the correct column sizes and flow rates to employed to extract the free solute fraction and separate it from non-retained sample components [12, 49, 70] . However, this limitation is being overcome as more information and experience is being obtained with this technique and further applications are being reported for this approach [47] [48] [49] [50] [51] [52] [53] . This additional information and set of applications should, in turn, allow for even more uses for this method in the future in areas that include biochemical or pharmaceutical research and clinical analysis [12, [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] .
Notes
5.1. The diol coverage of the modified Nucleosil Si-300 support that was used for the examples cited in this report was around 300 µmol diol/g silica. This value may differ when using other types of silica and will depend on the pore size and surface area of the support [72, 73] .
5.2. The degree of capture for a drug in ultrafast affinity extraction will vary with the flow rate, amount of immobilized binding agent, and size of the affinity microcolumn. The examples cited in this report typically had a capture efficiency of 95% or more when using HSA and AGP microcolumns [47,49].
5.3. When ultrafast affinity extraction is used with serum, these samples should be filtered (e.g., twice using syringe filters with 0.2 µm nylon membranes) prior to their combination with a drug or injection onto an HPLC system [52, 53] .
5.4. Although some immobilization schemes can lead to non-specific interactions of a solute to a support, it has been noted that this does not lead to any major effects in the measurement of binding constants by ultrafast affinity extraction [53] . This is the case because the affinity microcolumn is used only to capture and measure the free solute fraction. The actual binding event that is examined is the solution-phase interaction of the drug/solute with a soluble protein, and this process is not altered by non-specific interactions due to the support [53] . b These values were found by using Eq.
(1) when a point at the origin was included in the data set. [68, 94] a The values listed in this table are from Refs. [49, 54] . Other conditions were the same as in Table 1 . The values in parentheses represent a range of ± 1 S.D., as determined by error propagation.
b The global affinity constants for these drugs were calculated from data in the given references.
c This value represents the average association equilibrium constant for R-and S-verapamil at their high affinity site on HSA.
